INNOVIVA, INC. Payments to Acquire Marketable Securities
INNOVIVA, INC. (INVA) reported Payments to Acquire Marketable Securities of $35.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- INNOVIVA, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $25.00M.
- INNOVIVA, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $10.00M, a 71.16% decline year-over-year.
- INNOVIVA, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $11.22M, a 2.23% decline year-over-year.
- INNOVIVA, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $15.00M, a 200.00% increase year-over-year.
- INNOVIVA, INC. payments to acquire marketable securities for fiscal 2025 was $60.90M, a 2.15% increase from fiscal 2024.
- INNOVIVA, INC. payments to acquire marketable securities for fiscal 2024 was $59.62M, a 8.47% decline from fiscal 2023.
- INNOVIVA, INC. payments to acquire marketable securities for fiscal 2023 was $65.13M.
- INNOVIVA, INC. payments to acquire marketable securities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $35.00M 10-Q · filed 2026-08-05 | $46.22M derived: sum of 3 quarters · filed 2026-08-05 | $61.22M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-06 | $21.23M derived: sum of 2 quarters · filed 2026-05-06 | $36.23M derived: sum of 3 quarters · filed 2026-05-06 | $36.23M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $26.23M derived: sum of 2 quarters · filed 2026-02-25 | $26.23M derived: sum of 3 quarters · filed 2026-08-05 | $60.90M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.00M derived: sum of 2 quarters · filed 2026-08-05 | $49.67M 10-Q · filed 2025-11-05 | $61.16M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $34.67M 10-Q · filed 2026-08-05 | $46.16M derived: sum of 3 quarters · filed 2026-08-05 | $51.16M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $34.67M 10-Q · filed 2026-05-06 | $46.16M derived: sum of 2 quarters · filed 2026-05-06 | $51.16M derived: sum of 3 quarters · filed 2026-05-06 | $51.16M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $11.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $16.48M derived: sum of 2 quarters · filed 2026-02-25 | $16.48M derived: sum of 3 quarters · filed 2026-02-25 | $59.62M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.00M derived: sum of 2 quarters · filed 2025-11-05 | $48.14M 10-Q · filed 2025-11-05 | $53.14M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $43.14M 10-Q · filed 2025-08-06 | $48.14M derived: sum of 3 quarters · filed 2026-02-25 | $108.27M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $43.14M 10-Q · filed 2025-05-07 | $48.14M derived: sum of 2 quarters · filed 2026-02-25 | $108.27M derived: sum of 3 quarters · filed 2026-02-25 | $108.27M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $65.13M derived: sum of 2 quarters · filed 2026-02-25 | $65.13M derived: sum of 3 quarters · filed 2026-02-25 | $65.13M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $60.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $60.13M derived: sum of 2 quarters · filed 2024-11-06 | $60.13M 10-Q · filed 2024-11-06 | $60.13M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $0.00 10-Q · filed 2024-07-31 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | ||||
| 2021-12-31 | $15.90M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $15.90M derived: sum of 2 quarters · filed 2024-03-05 | $15.90M derived: sum of 3 quarters · filed 2024-03-05 | $15.90M 10-K/A · filed 2024-03-05 | $0.00 10-K · filed 2022-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $0.00 derived: sum of 2 quarters · filed 2021-10-27 | $0.00 10-Q · filed 2021-10-27 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $12.94M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $0.00 derived: sum of 2 quarters · filed 2021-10-27 | $12.94M 10-Q · filed 2021-10-27 | $13.94M derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $12.94M 10-Q · filed 2021-07-29 | $13.94M derived: sum of 3 quarters · filed 2022-03-17 | $132.92M derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-03-31 | $12.94M 10-Q · filed 2021-04-28 | $13.94M derived: sum of 2 quarters · filed 2022-03-17 | $132.92M derived: sum of 3 quarters · filed 2022-03-17 | $142.82M derived: sum of 4 quarters · filed 2022-03-17 | |
| 2019-12-31 | $993.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $119.98M derived: sum of 2 quarters · filed 2022-03-17 | $129.87M derived: sum of 3 quarters · filed 2022-03-17 | $231.91M 10-K/A · filed 2022-03-17 | |
| 2019-09-30 | $118.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $128.88M derived: sum of 2 quarters · filed 2020-10-28 | $230.92M 10-Q · filed 2020-10-28 | ||
| 2019-06-30 | $9.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $111.94M 10-Q · filed 2020-07-29 | |||
| 2019-03-31 | $102.04M 10-Q · filed 2020-04-29 | ||||
| 2018-12-31 | $71.86M 10-K · filed 2021-02-25 | ||||
| 2012-03-31 | $35.67M 10-Q · filed 2012-05-02 | $105.95M derived: sum of 2 quarters · filed 2012-05-02 | $160.91M derived: sum of 3 quarters · filed 2012-05-02 | $260.83M derived: sum of 4 quarters · filed 2012-05-02 | |
| 2011-12-31 | $70.28M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $125.24M derived: sum of 2 quarters · filed 2012-02-27 | $225.16M derived: sum of 3 quarters · filed 2012-02-27 | $301.56M 10-K · filed 2012-02-27 | |
| 2011-09-30 | $54.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $154.88M derived: sum of 2 quarters · filed 2011-11-02 | $231.28M 10-Q · filed 2011-11-02 | $281.13M derived: sum of 4 quarters · filed 2012-05-02 | |
| 2011-06-30 | $99.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | $176.32M 10-Q · filed 2011-08-03 | $226.16M derived: sum of 3 quarters · filed 2012-05-02 | $256.36M derived: sum of 4 quarters · filed 2012-05-02 | |
| 2011-03-31 | $76.41M 10-Q · filed 2012-05-02 | $126.25M derived: sum of 2 quarters · filed 2012-05-02 | $156.45M derived: sum of 3 quarters · filed 2012-05-02 | ||
| 2010-12-31 | $49.84M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $80.04M derived: sum of 2 quarters · filed 2012-02-27 | $183.90M 10-K · filed 2012-02-27 | ||
| 2010-09-30 | $30.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $134.06M 10-Q · filed 2011-11-02 | |||
| 2010-06-30 | $103.86M 10-Q · filed 2011-08-03 | ||||
| 2009-12-31 | $123.46M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |